Patients Stopping Anti-Obesity Medications Gain Back Pounds Four Times Faster Compared to Dieters

A recent study reveals that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who stop conventional diet and exercise plans.

Published data in a leading health publication points out that while overweight people often shed substantial amounts of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.

"People purchasing these medications must be informed of the danger of rapid rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.

That rate of recovery suggests a reversion to pre-treatment weight in about 18 months.

Analyzing Approaches

The study, which reviewed 37 of trials involving thousands of patients, contrasted the results of these new drugs with older methods.

The team emphasize that individuals who shed pounds through lifestyle changes alone generally see a slower weight regain—around 100 grams monthly—after stopping.

Explaining the Fast Rebound

Doctors believe the mode of action of the jabs accounts for the accelerated regain.

GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.

"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.

"Stopping of this hormone supplement results in appetite is no longer kept in check, making binge eating much more probable."

An Ongoing Condition?

Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.

A number of clinicians contend that, considering the likelihood of weight regain, the treatment might need to be long-term.

This perspective is supported by drug manufacturers, who state that the findings "underscore the chronic character of excess weight," similar to managing conditions like high blood pressure.

User Testimonies

Users who have stopped the jabs explain a intense return of appetite.

"I experienced a switch flipping and I was suddenly starving," described an individual.

This challenge is compounded if individuals have not developed sustainable dietary or behavioural changes during treatment.

Significant Adoption

Figures show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.

• Adoption is more common among women than men.
• The middle-aged age group shows the highest usage rates.
• Many obtain the medications through private healthcare rather than the NHS.

Ultimately, experts caution that while the jabs are effective agents for shedding pounds, they are not a magic solution and long-term success hinges on combined behavioural changes.